FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293109763> ?p ?o ?g. }

• W4293109763 abstract "Expanding access to effective antiretroviral therapy (ART) is a major tool for management of Human Immunodeficiency Virus (HIV) infection. However, rising levels of HIV drug-resistance have significantly hampered the anticipated success of ART in persons living with HIV (PLWH), particularly those from Africa. Though great strides have been made in Ghana toward achieving the UNAIDS 95-95-95 target, a substantial number of PLWH receiving ART have not attained viral suppression. This study investigated patterns of drug resistance mutations in ART naïve as well as ART-experienced PLWH receiving first-line regimen drugs from Ghana. In a cross-sectional study, blood samples were collected from HIV-1 infected adults (≥18 years) attending HIV/AIDS clinic at the Eastern Regional Hospital, Koforidua, Ghana from September to October 2017. Viral RNA isolated from plasma were subjected to genotypic drug resistance testing for Protease Inhibitors (PI), Reverse Transcriptase Inhibitors (RTI), and Integrase Strand Transfer Inhibitors (INSTI). A total of 95 (84 ART experienced, 11 ART naïve) HIV-1 infected participants were sampled in this study. Sixty percent (50/84) of the ART-experienced participants were controlling viremia (viral load < 1,000 copies/ml). Of the 95 patient samples, 32, 34, and 33 were successfully sequenced for protease, reverse-transcriptase, and integrase regions, respectively. The dominant HIV-1 subtypes detected were CRF02_AG (70%), and A3 (10%). Major drug resistance associated mutations were only detected for reverse transcriptase inhibitors. The predominant drug resistance mutations were against nucleos(t)ide reverse transcriptase inhibitors (NRTI)-M184V/I and non-nucleos(t)ide reverse transcriptase inhibitors (NNRTI)-K103N. In the ART-experienced group, M184V/I and K103N were detected in 54% (15/28) and 46% (13/28) of individuals, respectively. Both mutations were each detected in 33% (2/6) of ART naïve individuals. Multiclass resistance to NRTI and NNRTI was detected in 57% of ART-experienced individuals and two ART naïve individuals. This study reports high-level resistance to NNRTI-based antiretroviral therapy in PLWH in Ghana. However, the absence of major PI and INSTI associated-mutations is a good signal that the current WHO recommendation of Dolutegravir in combination with an NRTI backbone will yield maximum benefits as first-line regimen for PLWH in Ghana." @default.
• W4293109763 created "2022-08-26" @default.
• W4293109763 creator A5020783319 @default.
• W4293109763 creator A5026898236 @default.
• W4293109763 creator A5030963556 @default.
• W4293109763 creator A5037338533 @default.
• W4293109763 creator A5040819317 @default.
• W4293109763 creator A5044005463 @default.
• W4293109763 creator A5044227923 @default.
• W4293109763 creator A5048494601 @default.
• W4293109763 creator A5050778947 @default.
• W4293109763 creator A5055405608 @default.
• W4293109763 creator A5063464944 @default.
• W4293109763 creator A5063513447 @default.
• W4293109763 creator A5066805703 @default.
• W4293109763 creator A5072297395 @default.
• W4293109763 creator A5085611805 @default.
• W4293109763 creator A5085849066 @default.
• W4293109763 creator A5087178931 @default.
• W4293109763 date "2022-08-25" @default.
• W4293109763 modified "2023-10-01" @default.
• W4293109763 title "High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study" @default.
• W4293109763 cites W1123605175 @default.
• W4293109763 cites W1969028669 @default.
• W4293109763 cites W2024161781 @default.
• W4293109763 cites W2048253923 @default.
• W4293109763 cites W2058243043 @default.
• W4293109763 cites W2060978056 @default.
• W4293109763 cites W2087757756 @default.
• W4293109763 cites W2097245338 @default.
• W4293109763 cites W2109046728 @default.
• W4293109763 cites W2135450624 @default.
• W4293109763 cites W2143028771 @default.
• W4293109763 cites W2154164013 @default.
• W4293109763 cites W2156127238 @default.
• W4293109763 cites W2170218446 @default.
• W4293109763 cites W2185029798 @default.
• W4293109763 cites W2557523555 @default.
• W4293109763 cites W2766501109 @default.
• W4293109763 cites W2773554166 @default.
• W4293109763 cites W2793269587 @default.
• W4293109763 cites W2883869563 @default.
• W4293109763 cites W2890735509 @default.
• W4293109763 cites W2898453025 @default.
• W4293109763 cites W2903314774 @default.
• W4293109763 cites W2981250909 @default.
• W4293109763 cites W3005926734 @default.
• W4293109763 cites W3137211483 @default.
• W4293109763 cites W4210514683 @default.
• W4293109763 cites W4236479494 @default.
• W4293109763 doi "https://doi.org/10.3389/fmicb.2022.973771" @default.
• W4293109763 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36090108" @default.
• W4293109763 hasPublicationYear "2022" @default.
• W4293109763 type Work @default.
• W4293109763 citedByCount "2" @default.
• W4293109763 countsByYear W42931097632022 @default.
• W4293109763 countsByYear W42931097632023 @default.
• W4293109763 crossrefType "journal-article" @default.
• W4293109763 hasAuthorship W4293109763A5020783319 @default.
• W4293109763 hasAuthorship W4293109763A5026898236 @default.
• W4293109763 hasAuthorship W4293109763A5030963556 @default.
• W4293109763 hasAuthorship W4293109763A5037338533 @default.
• W4293109763 hasAuthorship W4293109763A5040819317 @default.
• W4293109763 hasAuthorship W4293109763A5044005463 @default.
• W4293109763 hasAuthorship W4293109763A5044227923 @default.
• W4293109763 hasAuthorship W4293109763A5048494601 @default.
• W4293109763 hasAuthorship W4293109763A5050778947 @default.
• W4293109763 hasAuthorship W4293109763A5055405608 @default.
• W4293109763 hasAuthorship W4293109763A5063464944 @default.
• W4293109763 hasAuthorship W4293109763A5063513447 @default.
• W4293109763 hasAuthorship W4293109763A5066805703 @default.
• W4293109763 hasAuthorship W4293109763A5072297395 @default.
• W4293109763 hasAuthorship W4293109763A5085611805 @default.
• W4293109763 hasAuthorship W4293109763A5085849066 @default.
• W4293109763 hasAuthorship W4293109763A5087178931 @default.
• W4293109763 hasBestOaLocation W42931097631 @default.
• W4293109763 hasConcept C104317684 @default.
• W4293109763 hasConcept C114851261 @default.
• W4293109763 hasConcept C126322002 @default.
• W4293109763 hasConcept C142462285 @default.
• W4293109763 hasConcept C14430832 @default.
• W4293109763 hasConcept C156719811 @default.
• W4293109763 hasConcept C159047783 @default.
• W4293109763 hasConcept C182707283 @default.
• W4293109763 hasConcept C2776185481 @default.
• W4293109763 hasConcept C2777302000 @default.
• W4293109763 hasConcept C2777351918 @default.
• W4293109763 hasConcept C2778451633 @default.
• W4293109763 hasConcept C2779502633 @default.
• W4293109763 hasConcept C2781143361 @default.
• W4293109763 hasConcept C2781413609 @default.
• W4293109763 hasConcept C2909970146 @default.
• W4293109763 hasConcept C2993143319 @default.
• W4293109763 hasConcept C3013748606 @default.
• W4293109763 hasConcept C49105822 @default.
• W4293109763 hasConcept C54355233 @default.
• W4293109763 hasConcept C71924100 @default.
• W4293109763 hasConcept C86803240 @default.
• W4293109763 hasConcept C89423630 @default.
• W4293109763 hasConceptScore W4293109763C104317684 @default.

• next